The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 11, 2013
Filed:
Apr. 20, 2008
Sarah L. Gaffen, Amherst, NY (US);
Fang Shen, Amherst, NY (US);
Walter Hanel, Stony Brook, NY (US);
Jill Kramer, Glen Oaks, MA (US);
James P. Malone, Buffalo, NY (US);
Michael Wittekind, Bainbridge Island, WA (US);
Raymond Paxton, Bellevue, WA (US);
Sarah L. Gaffen, Amherst, NY (US);
Fang Shen, Amherst, NY (US);
Walter Hanel, Stony Brook, NY (US);
Jill Kramer, Glen Oaks, MA (US);
James P. Malone, Buffalo, NY (US);
Michael Wittekind, Bainbridge Island, WA (US);
Raymond Paxton, Bellevue, WA (US);
Amgen Inc., Thousand Oaks, CA (US);
Research Foundation of the State University of New York, Amherst, NY (US);
Abstract
The invention provides isolated Pre-Ligand Assembly Domain (PLAD) polypeptides comprising an amino acid sequence of a domain (e.g., a Fibronectin Ill-like domain) of an IL-17 Receptor (IL-17R) family member, wherein the PLAD polypeptide inhibits multimerization of a receptor complex comprising an IL-17R family member. Also provided are isolated PLAD-binding polypeptides, e.g., antibodies and avimers, which specifically bind to a PLAD polypeptide described herein. Related chimeric proteins, conjugates, nucleic acids, vectors, and host cells are provided herein. Further provided are methods of treating an inflammatory or autoimmune disease, methods of inhibiting IL-17-mediated signal transduction, methods of inhibiting IL-17 ligand binding, methods of inhibiting multimerization of IL-17R complexes, and methods of inhibiting the production of at least one cytokine, chemokine, matrix metalloproteinase, or other molecule associated with IL-17 signal transduction are provided.